Educational Videos, Reports & Slides

Biliary Atresia
Hepatitis B
Hepatitis C
Hepatic Encephalopathy

Hepatocellular Carcinoma (Liver Cancer)
Liver Disease
Lysosomal Acid Lipase Deficiency (LALD)

Available for FREE download from the Canadian Liver Foundation:



BILIARY ATRESIA:


"The Canadian Biliary Atresia Registry (CBAR) is a collaboration between the Canadian Pediatric Hepatology Research Group (CPHRG) and the Canadian Association of Pediatric Surgeons (CAPS), the two well-established networks in Canada involved with the care of children with biliary atresia."

To access more information for Physicians and Investigators, click here.


HEPATITIS B





 
INTERNATIONAL HEPATITIS B CURE WORKSHOP 2016
This one-day workshop will bring together global inter-disciplinary experts to enhance the field of hepatitis B research and to provide an interactive platform to achieve the goal of global hepatitis B cure. The meeting will include invited lectures, oral abstract presentations, poster view sessions, Q&A sessions, roundtable discussions and debates.

The slides and videos are now available online. Click here 


INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2016

The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration

The slide and videos are now available online. Click here

Back to the top


HEPATITIS C:


HEPATITIS C EDUCATION NATIONAL NEEDS ASSESSMENT

Canadian Liver Foundation and Canadian Association for the Study of the Liver, in partnership with the Canadian Association of Hepatology Nurses
(October 2015)

Assessment of the current knowledge of healthcare providers in the area of hepatitis C management, including screening and treatment using new antivirals, as well as the educational needs of healthcare providers at a national level.

Go to liver.ca/HepCReport to download.

Educational grant provided by AbbVie Corporation.



HEPATITIS C SCREENING AND TESTING

Morris Sherman, MD BCh PhD FRCP(C)
(November 2015)

 Click here to download.








6th CANADIAN SYMPOSIUM ON HEPATITIS C VIRUS 2017

Delivering a Cure for Hepatitis C Infection: What are the Remaining Gaps?

The videos are now available online. Click here. 









5TH CANADIAN SYMPOSIUM ON HEPATITIS C VIRUS 2016

We're Not Done Yet - Remaining Challenges in Hepatitis C

The videos are now available online. Click here.









 2ND HEPATITIS CURE & ERADICATION MEETING 2015
The science of hepatitis research is revolutionizing our ability to cure and eliminate hepatitis. This workshop brought together global inter-disciplinary experts to provide a framework for how science can inform public policy to achieve the goal of global hepatitis eradication. 

The slides and videos are now available online. Click here







1ST HEPATITIS CURE & ERADICATION MEETING 2014
Leading experts from Canada, the Netherlands, China, Italy, USA, Australia and Germany lead this two-day translational and public health meeting with the objective to decrease the burden of disease, to simplify treatment and to cure and eradicate hepatitis. The Canadian Liver Foundation was please to provide academic endorsement of this educational event.

The slides and videos are now available online. Click here.


3RD OPTIMIZE WORKSHOP: USING DAAS IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS
This workshop focuses on current and emerging direct-acting individuals (DAAs) which promises to impact greatly the management of hepatitis C both prior to and after transplantation. Patients with cirrhosis, patients waiting on lists for liver transplantation, and liver recipients represent populations with a significant need for effective new therapies.

The slides and videos are now available online. Click here.


INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2016

The objective of this meeting is to enhance elimination of viral hepatitis worldwide from the perspective of the medical community. This meeting will address obstacles on the elimination of viral hepatitis along with strategies for success. Following the framework of the recent World Health Organization goals, the meeting will provide an ideal forum for presenting plans to address the elimination of Hepatitis B and C, with concrete objectives, tangible goals and measurable outcomes. The outcomes will be translated to an updated version of the Toronto Declaration

The slide and videos are now available online. Click here


EVOLUTION AND REVOLUTION: CURRENT ISSUES IN HIV AND HEPATITIS C VIRUS CO-INFECTION

Edited by: Marina B. Klein, MD MSc FRCP(C)
Posted with permission from: McGill University Health Centre
(May 2013, Updated January 2014)

Chapter 1 - HIV-Hepatitis C Virus Co-Infection: An Evolving Epidemic - Marina B. Klein, MD, MSc, FRCP(C) 
Chapter 2 - Management of HIV Infection in HIV/Hepatitis C Virus Co-Infected Patients - Mark Hull, MD, MHSc, FRCPC 
Chapter 3 - Management of Hepatitis C Virus Infection in HIV/Hepatitis C Virus Co-Infected Patients - Marie-Louise Vachon, MD, MSc 
Chapter 4 - Hepatitis C Virus Therapy: Direct Acting Antiviral Agents in Co-Infected Individuals - Curtis Cooper, MD, FRCPC 
Chapter 5 - Drug Interactions with Directly Acting Antivirals for Hepatitis C Virus: An Overview & Challenges in HIV/Hepatitis C Virus Co-Infection - Alice Tseng, Pharm.D., FCSHP, AAHIVP 
Chapter 6 - Complicated Cases - David Fletcher, MD 
Chapter 7 - Future Trials of Hepatitis C Therapy in the HIV Co-Infected - Stephen D. Shafran, MD, FRCPC, FACP 
Chapter 8 - Hepatitis C Virus Infection in Marginalized Populations - Brian Conway, MD, FRCPC 
Chapter 9 - HIV/Hepatitis C Virus Co-Infection: Through the Eyes of a Co-Infected Hemophiliac - I.D. 
Chapters 1 - 9 Inclusive, Complete Slide Deck - Evolution and Revolution: Current Issues in HIV and Hepatitis C Virus Co-Infection 

Back to the top


HEPATIC ENCEPHALOPATHY:

HEPATIC ENCEPHALOPATHY: EXPLORE THE NEUROPSYCHIATRIC CONSEQUENCES OF CIRRHOSIS
Prepare by: Dr. Christopher Rose, Dr. Hermant Shah, Dr. Puneeta Tandon and Dr. Philip Wong (June 2017)

(Click on the above image and save the Powerpoint Show to view the slides)

Module 1:
Chronic Liver Disease & Cirrhosis: An Introduction
Hepatic Encephalopathy: Overview
Hepatic Encephalopathy: Pathophysiology
Hepatic Encephalopathy: Clinical Classification
Covert Hepatic Encephalopathy: West Haven/Conn Score (0-1)
Covert Hepatic Encephalopathy: Testing


(Click on the above image and save the Powerpoint Show to view the slides)

Module 2:
Overt HE
Nonabsorbable Disaccharides: Lactulose
Dietary Modification: BCAA’s(Branched-Chain Amino Acids) Nutrition in cirrhosis

For a video version of the slides with voice-over narration, please click here.

Back to the top


HEPATOCELLULAR CARCINOMA (LIVER CANCER):

CANADIAN ASSOCIATION FOR THE STUDY OF THE LIVER HEPATOCELLULAR CARCINOMA MEETING: CONSENSUS, CONTROVERSIES AND FUTURE DIRECTIONS
The slides and videos are now available online. Click here

Back to the top


LIVER DISEASE:

LIVER DISEASE IN CANADA: A CRISIS IN THE MAKING
(April 2013)

Canadian Liver Foundation sounds the alarm on looming public health crisis

The Canadian Liver Foundation released "Liver Disease in Canada: A Crisis in the Making" - the first comprehensive report on liver disease in Canada. Findings include close to a 30 per cent increase in deaths from liver disease in the eight years from 2000-2007, with Ontario, Quebec, Alberta and British Columbia being hit hardest.

Click here to download.

Back to the top



LYSOSOMAL ACID LIPASE DEFICIENCY (LALD)

Webinar : The Role of Pathology in Diagnosing Lysomal Acid Lipase Deficiency (LAL-D)
Presented by: Dr. Subrata Chakrabarti, Chair, Department of Pathology and Laboratory Medicine at Western University and Chief of Pathology and Laboratory Medicine at London Health Sciences Centre & St. Joseph's Health Care, London, Ontario, Canada.

Lysosomal Acid Lipase Deficiency (LAL-D) is an autosomal recessive lysosomal storage disorder [previously known as Wolman Disease (infants) and Cholesteryl Ester Storage Disease (children and adults)]. In pediatric and adult patients, nearly 50% progress to fibrosis, cirrhosis or liver transplant within 3 years of onset of symptoms.

Healthcare professional access to webinar video, please click here.

Back to the top


Note: The information links above have been chosen based on their content, source and potential usefulness for our site visitors and are provided here as a public service with regard to liver-related issues. However, the Canadian Liver Foundation assumes no responsibility for any information on these sites and the inclusion of a link on this page does not constitute an endorsement of any sponsoring organization or individual by the Canadian Liver Foundation.

VOLUNTEER
DONATE NOW
YOUR STORY